The Value of Lung Biopsy in Infants up to 3 Months With Diffuse Lung Disease in a Resource‐Limited Setting
Canadian Respiratory Journal · 2026
DOI: 10.1155/carj/1509295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2026. Verfasst von Pierre Goussard und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Lung, Respiratory Distress Syndrome, Newborn. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Neonatal lung biopsy guides management of unusually severe, diffuse lung disease with an uncertain diagnosis. Childhood interstitial lung disease (chILD) constitutes a diverse group of uncommon respiratory diseases which are associated with major morbidity and mortality. The incidence, outcome and mortality of chILD and other severe respiratory diseases in resource‐limited settings (RLS) are unclear.
Objective
This retrospective, descriptive study examined lung biopsy in an RLS on infants up to 3 months of age to diagnose and facilitate management. This study included neonates with severe respiratory distress not responding to surfactant replacement.
Results
Lung biopsy was diagnostic in 94% (29/31) of patients without procedure‐related mortality. The mean gestational age at birth was 35.8 weeks (SD ± 4.6). The mean presentation age was 20 days of life (IQR 1–28). Of 31 participants, 16% ( n = 5) had histological findings in keeping with pulmonary interstitial glycogenosis (PIG) only. Sixteen percent ( n = 5) of biopsies showed findings in keeping with adenosine triphosphate (ATP)–binding cassette subfamily A member 3 (ABCA3) deficiency in combination with features of PIG on electron microscopy. Surfactant protein (SFTP)‐B deficiency and undefined surfactant deficiency were equally prevalent (6% ( n = 2). Pulmonary hypertension (PHT) featured in 61% ( n = 17) of infants. Genetic testing was performed on 29% ( n = 9) of infants, with 56% ( n = 5) showing normal results. The cohort mortality was 42% ( n = 13).
Conclusions
ChILD should be considered in neonates with severe respiratory distress and PHT not responding to surfactant replacement. Lung biopsy is safe and diagnostic and may prevent long and futile treatment. Histopathological diagnosis frequently assists treatment decisions. Future multicentre studies should include children from an RLS to collect information on diagnoses, genetics and treatment responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, sun.ac.za.
- Department of Pathology, Division of Anatomical Pathology, Tygerberg Hospital, National Health Laboratory Service, Faculty of Medicine and Health Science, Stellenbosch University, Cape Town, South Africa, sun.ac.za.
- Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, sun.ac.za.
- Division of Human Genetics, National Health Laboratory Service and School of Pathology, University of the Witwatersrand, Johannesburg, South Africa, wits.ac.za.
- Department of Surgical Sciences, Division of Cardiothoracic Surgery, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, sun.ac.za.
- Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, chop.edu.
ORCID-Profile: Pierre Goussard, Pawel Schubert, Lizelle van Wyk, Lynn Booysen, André Gie, Michael Urban, Jacques Janson, Savvas Andronikou, Ernst Eber
Zitieren
APA
Goussard, P., Schubert, P., van Wyk, L., Booysen, L., Gie, A., Urban, M., Janson, J., Andronikou, S., & Eber, E. (2026). The Value of Lung Biopsy in Infants up to 3 Months With Diffuse Lung Disease in a Resource‐Limited Setting. Canadian Respiratory Journal. https://doi.org/10.1155/carj/1509295
Vancouver
Goussard P, Schubert P, van Wyk L, Booysen L, Gie A, Urban M, et al. The Value of Lung Biopsy in Infants up to 3 Months With Diffuse Lung Disease in a Resource‐Limited Setting. Canadian Respiratory Journal. 2026. doi:10.1155/carj/1509295
BibTeX
@article{Goussard2026,
author = {Goussard, Pierre and Schubert, Pawel and van Wyk, Lizelle and Booysen, Lynn and Gie, André and Urban, Michael and Janson, Jacques and Andronikou, Savvas and Eber, Ernst},
title = {The Value of Lung Biopsy in Infants up to 3 Months With Diffuse Lung Disease in a Resource‐Limited Setting},
journal = {Canadian Respiratory Journal},
year = {2026},
doi = {10.1155/carj/1509295}
}
EUVIMED